is dreaming of Nicosan4All ;-)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well said! Thanks.
Thanks for this... are you able at this time to disclose who is participating in the new interim management team? Also, will you be able to take some pics at the 'tour' tomorrow?
Cerrone Vs Henderson Video Xechem International Inc Eduardo Da Silva
(GOIG.PK) Power 3 Medical Products Inc.
I do not know what the heck this is... u may wish to form your own opinions and let us know... ~ Steve
Francis was the first to shoot his mouth off, arguing that Arsenal still lack a natural goalscorer in their squad, although acknowledging Eduardo da Silva was sitting on the bench.. (PWRM.OB) Xechem International Inc. September 30, 2009
| By Cristian Dale In Online Business | by Cristian DaleIt seems that people are so conscious with their budgets now days that even ads are not getting clicked anymore! The people who used to pay $99 for ridiculous get rich e-books have somehow vanished from our planet and moved on…Cashing in on the Internet a few years back was child’s play. (XKEMQ.PK) IN CONTROL SECURITY, (INCL.PK) SINO PAYMENTS, INC. In a couple of days you could slap a website together and be making money within weeks.
http://wilson.asukalover88.com/cerrone-vs-henderson-video-xechem-international-inceduardo-da-silvamedical-products-inc/
Swiss help developing nations combat fake drugs
October 12, 2009 - 9:33 PM
Nations join forces to check counterfeit boom A team of Swiss engineers and pharmacists has built a low-cost machine, due to be launched in Mali, aimed at helping poor countries detect counterfeit medicines.
Fake drugs are a growing public health problem, especially for developing nations. The World Health Organization (WHO) says over 30 per cent of medicines sold in many African countries, as well as parts of Asia and Latin America, may be counterfeit.
According to the US-based Centre for Medicines in the Public Interest, counterfeit drug sales will reach $75 billion (SFr77.1 billion) globally in 2010, an increase of more than 90 per cent compared with 2005.
Counterfeiting is greatest in those regions where medicines' regulatory and enforcement systems are weakest. In Africa, where almost 80 per cent of drugs are imported, fake drugs and the lack of means to analyse their quality can have catastrophic consequences.
The WHO says at least 200,000 lives could be saved every year if there were no fake medicines. In 2008 more than 80 babies in Nigeria died from teething medicine that contained the toxic coolant diethylene glycol.
To help prevent such illnesses and deaths, the Geneva-Lausanne School of Pharmacy, together with the Fribourg College of Engineering and Architecture, have come up with a unique quality-control solution for developing countries.
Their aim was to design a tool that was cheap, simple, sturdy and able to cope with extreme weather conditions.
The low-cost analytical device uses capillary electrophoresis, a recognised technique which separates molecules by size and electrical charge.
The Swiss counterfeit detection machine (unige.ch)Low cost
"The technique is extremely interesting as it uses little material and has a low analytical cost, but it's not that well known," Serge Rudaz, project coordinator at Geneva's School of Pharmacy, told swissinfo.ch.
Such instruments already exist on the market but are extremely expensive – SFr60,000-80,000 ($58,400-78,000) – and are difficult to maintain. The new machine costs only SFr8,000.
After three years' development the bright-red instrument will be sent in early November to the National Health Laboratory at Bamako University in Mali, which has special cooperation agreements with Geneva University.
Swiss engineers will travel to Bamako to set up the device and train colleagues from Mali to guarantee the project's longevity, Rudaz explained.
Counterfeit drugs are a major problem in Mali. Many are imported from India and China, where production conditions don't always meet international pharmaceutical standards. Mali's extreme weather conditions can also cause badly stored drugs to deteriorate.
Bamako laboratory
The National Health Laboratory's existing methods for detecting counterfeit medicines are expensive and technically demanding. The laboratory has growing difficulties in obtaining reasonably priced high-quality organic solvents, for example.
The new machine, which uses a tiny amount of solvent and small quantities of water in the analysis process, is much simpler to operate and maintain, according to Rudaz.
In the development phase the apparatus was tested on a selection of 20 well-known drugs, including Amoxicillin, used to treat bacterial infections, the antibiotic Cotrimazol, HIV antiretroviral treatments and Quinidine, an anti-malarial drug.
"But in principle it can test any kind of drug," he said.
The scientists are already banking on the success of their project and have set up an association, Pharmelp, to be able to propose their low-cost drug control approach to other developing countries.
Rudaz is certain that word of mouth in the African medical world will ensure its success. In the meantime he has already been contacted by interested partners from Madagascar and Cambodia.
Simon Bradley, swissinfo.ch
http://www.swissinfo.ch/eng/front/Swiss_help_developing_nations_combat_fake_drugs.html?siteSect=105&sid=11341642&cKey=1255376004000&ty=st
UNITED STATES BANKRUPTCY COURT
- NORTHERN DISTRICT OF ILLINOIS -
THE HONORABLE JACK SCHMETTERER, PRESIDING
LOCATION: COURTROOM 682
EASTERN DIVISION
Thursday, October 22, 2009
Updated 10/12/2009 @ 10:23:AM CST
11:30 AM
08bk30512
This[191]
Orig[138] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 9,10 Filed by Douglas S Draper on behalf of Xechem Inc.
08bk30512
This[192]
Orig[136] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 7 Filed by Douglas S Draper on behalf of Xechem Inc.
08bk30512
This[195] XECHEM INC CH. 11
Status Hearing Order Scheduling . Chapter 11 Plan due by 10/21/2009. Disclosure Statement due by 10/21/2009. Status hearing
08bk30512
This[187] XECHEM INC CH. 11
Status Hearing Order(Amending claim#25) Scheduling (RE: [167] Motion for Leave). Complaint Deadline 9/18/2009. Status hearing
08bk30512
This[188] XECHEM INC CH. 11
Status Hearing Hearing Continued . Status hearing
08bk30512
This[189]
Orig[138] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 9,10 Filed by Douglas S Draper on behalf of Xechem Inc.
08bk30512
This[189]
Orig[136] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 7 Filed by Douglas S Draper on behalf of Xechem Inc.
08bk30512
This[190]
Orig[137] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 6 Filed by Douglas S Draper on behalf of Xechem Inc.
09ap00581
This[7] XECHEM INC 08BK30512, XECHEM INTERNATIONAL, INC. V. MISRA PH D AP
Status Hearing Adversary case 09-00581. (81 (Subordination of claim or interest)): Complaint by XECHEM International, Inc. against Renuka Misra Ph D. Fee Amount $250. Status hearing
08bk30513
This[137]
Orig[69] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 42 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[137]
Orig[67] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 57 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[137]
Orig[74] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 25 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[137]
Orig[70] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 32 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[137]
Orig[65] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 45 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[137] XECHEM INTERNATIONAL, INC. CH. 11
Hearing Continued (RE: [119] Allow Claims).
08bk30513
This[137]
Orig[64] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 33 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[137]
Orig[76] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) of Omnibus Objection to Late-Filed Proofs of Claim Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[137]
Orig[71] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 30 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[137]
Orig[75] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) of Omnibus Objection to Overstated Proofs of Claim Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[138]
Orig[82] XECHEM INTERNATIONAL, INC. CH. 11
Incorrect PDF-Filer Notified to Refile Notice of Motion and Motion to Disallow Omnibus Objection to Overstated Proofs of Claim Filed by Stephen A Metz on behalf of Renuka Misra Ph D.
08bk30513
This[141]
Orig[71] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 30 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [71] Objection to Claim, [103] Amended Objection to Claim).
08bk30513
This[142]
Orig[70] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 32 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [70] Objection to Claim, [100] Amended Objection to Claim).
08bk30513
This[143]
Orig[72] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 41 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [72] Objection to Claim, [106] Amended Objection to Claim).
08bk30513
This[144]
Orig[69] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 42 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [69] Objection to Claim).
08bk30513
This[145] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Motion and Motion for Agreed Order Objection to Proof of Claim Number 30 Filed by Toxikon Corporation [P-71] Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[149]
Orig[64] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 33 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[155]
Orig[66] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 41 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[155]
Orig[72] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 41 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
... and I imagine also hundreds of thousands of young souls still among the living...
Aflac raises $1M through FacebookSilicon Valley / San Jose Business Journal
Wednesday, October 7, 2009, 2:17pm PDT
Aflac Inc. raised more than $1.16 million for the Aflac Cancer Center through a matching grant campaign with the Causes application on Facebook.
The Columbus, Ga.-base insurance company said the fundraiser was the largest sponsored campaign in the history of Causes. Prior to the launch of Aflac's pediatric cancer Cause, the largest matching grant on a Palo Alto-based Facebook Inc. Cause site was $100,000.
Aflac Chairman and CEO Dan Amos contributed $100,000. His donation, like all the others, was matched dollar-for-dollar by Aflac (NYSE: AFL). NASCAR driver Carl Edwards, who is sponsored by Aflac, contributed his portion of his team's earnings from the Sept. 6 race at the Atlanta Motor Speedway.
The Aflac Cancer Center treats more than 350 new cancer patients every year. It also provides the largest sickle cell disease program in America, with 1,635 active cases and has cured more children of sickle cell disease than any treatment center in the nation.
Atlanta Business Chronicle
http://sanjose.bizjournals.com/sanjose/stories/2009/10/05/daily65.html
Wonderful to read your post - and hope that in this thing called your LIFE that this is all working out equally wonderful.
Sickle-Cell Anemia: Vaccines in Wealthy Countries May Save Lives of Children in Africa, Study Suggests
Eric Grave/Photo Researchers
Published: September 14, 2009
In Africa, more than 90 percent of children with sickle-cell anemia die before their illness is diagnosed.
Health Guide: Sickle Cell AnemiaA new study, published last week in the British journal Lancet, showed that invasive bacteria were an important cause of those children’s deaths and that many of the bacteria were the same kinds that affect children in wealthy countries, which have vaccines against them.
Those findings suggest that new antibacterial vaccines used in the wealthy world could save the lives of many African children, the authors wrote. (Old vaccines against measles, mumps and polio are cheap, but newer antibacterial ones like Hib and Prevnar are usually much more expensive, limiting their use in poor countries.)
Researchers also said that using antibiotics among these children as a preventive measure, which is controversial because of fears of creating antibiotic resistance, could save lives.
Researchers took blood from more than 38,000 children admitted to one hospital in Kenya and screened it for both bacterial infection and sickle-cell anemia. They found that children with sickle-cell anemia developed a severe infection about six times as often as children without.
The study was sponsored by the Wellcome Trust, a leading British foundation focusing on third-world health.
The sickle-cell trait partly protects children against malaria, but sickle-cell disease is excruciatingly painful and often fatal. About 1 in 600 black Americans has it; in some parts of Africa, more than 1 child in 100 does.
http://www.nytimes.com/2009/09/15/health/15glob.html?_r=1
Thanx rotweiler & LoChute
UNITED STATES BANKRUPTCY COURT
- NORTHERN DISTRICT OF ILLINOIS -
THE HONORABLE JACK SCHMETTERER, PRESIDING
LOCATION: COURTROOM 682
EASTERN DIVISION
Friday, October 09, 2009
Updated 09/27/2009 @ 07:38:PM CST
11:00 AM
08bk30513
This[148] XECHEM INTERNATIONAL, INC. CH. 11
Amended Objection to (related document(s): [66] Objection to Claim) Filed by Monika J. Machen on behalf of The Official Committee of Unsecured Creditors (Attachments: # (1) Exhibit Exh A - Proof of Claim# (2) Exhibit Exh B - 3/10/09 Letter# (3) Exhibit Exh C - Discovery Request) (Machen, Monika)
08bk30513
This[139]
Orig[66] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 41 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[139]
Orig[72] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 41 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
fox... FOX! once again, u r the master! Thank You for your dilligence and perserverance... now it would seem the not so Swift one has gone a few steps too far on our dime. Congratulations on your discovery, and with Monty already in full swing on adjacent fronts this whole scene is about to take on a much more interesting phase imo. Good Work and Thanks to all involved here in helping make Nicosan available to those who need it.
(fyi I have very limited and only occasional internet access since last November)
So where did he get the tenacity to push so hard...?
"Well it's easier to do when you're a true believer, and when you believe that what you're doing is worthwhile... There was never any question in my mind that I was doing the right thing, or was on the side of the angels. Never a question in my mind."
While this recent quote is attributed to Hugh Hefner and his push for social change, many of us would feel that perhaps LaMonte could utter the same.
UNITED STATES BANKRUPTCY COURT
- NORTHERN DISTRICT OF ILLINOIS -
THE HONORABLE JACK SCHMETTERER, PRESIDING
LOCATION: COURTROOM 682
EASTERN DIVISION
Thursday, September 24, 2009
Updated 09/14/2009 @ 11:08:AM CST
11:00 AM
09ap00358
This[17] XECHEM INC 08BK30512, XECHEM INTERNATIONAL, INC. V. NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND AP
Status Hearing Hearing Continued . Status hearing
09ap00358
This[18]
Orig[10] XECHEM INC 08BK30512, XECHEM INTERNATIONAL, INC. V. NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND AP
Notice of Motion and Motion to Dismiss Adversary Proceeding Filed by B Lane Hasler on behalf of Uford S. Inyang, National Institute for Pharmaceutical Research and Development, Babatunde Osotimehim.
09ap00358
This[21] XECHEM INC 08BK30512, XECHEM INTERNATIONAL, INC. V. NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND AP
Status Hearing Hearing Continued Status hearing
New Drug to Treat Sickle Cell Crisis Begins Pilot Study in Patients
GAITHERSBURG, Md.--(Business Wire)--
GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is
developing a new class of glycobiology-based therapies for a broad range of
indications, today announced that a pilot study of the company`s lead candidate,
GMI-1070, is underway in sickle cell patients. The first patients in this pilot
study were treated at Children`s Hospital & Research Center Oakland in
California.
GMI-1070 is a first-in-class pan-selectin inhibitor intended to treat
vaso-occlusive crisis by inhibiting the inflammatory processes underlying cell
adhesion. The pilot study will evaluate the safety and pharmacokinetics of
GMI-1070, and is also designed to measure the effect of GMI-1070 on blood flow
and biomarkers of inflammation in patients with sickle cell disease. The trial
will enroll up to twenty sickle cell disease patients not experiencing
vaso-occlusive crisis.
"The dosing of patients with this novel agent marks an important milestone in
the advancement of an exciting and much-needed approach to addressing sickle
cell crisis," said Helen Thackray, M.D., GlycoMimetics` Vice President of Drug
Development. "The data we obtain from this pilot study will enable additional
studies in sickle cell patients in the midst of vaso-occlusive crisis."
"GMI-1070 appears to have interesting potential as a new treatment for
vaso-occlusive crisis in sickle cell patients. Vaso-occlusive crisis is a
painful and life-threatening complication of sickle cell disease that truly
lacks effective treatment options," said Lori Styles, M.D.,
Hematologist/Oncologist and the lead clinical investigator at Children`s for
this program. "We are pleased to have the opportunity to be a leading clinical
investigation site in the evaluation of GMI-1070."
GlycoMimetics recently announced the completion of two Phase 1 clinical studies
of GMI-1070`s safety in healthy volunteers. Clinical investigators reported no
serious adverse events in either of the two studies.
About GMI-1070
GlycoMimetics` lead compound, GMI-1070, is a rationally designed glycomimetic
inhibitor of E-, P- and L-selectins, and inhibits a key early step in the
inflammatory process leading to leukocyte adhesion and recruitment to inflamed
tissue. GMI-1070 has been shown to be active in several models of diseases in
which leukocyte adhesion and activation play a key role, including
vaso-occlusive crisis of sickle cell disease. By inhibiting selectin
interactions, GMI-1070 may be able to decrease the enhanced cell adhesion that
results in vaso-occlusive crisis. In pre-clinical studies, GMI-1070 restored
blood flow to affected vessels of sickle cell animals experiencing
vaso-occlusive crisis. GMI-1070 is also being evaluated in preclinical studies
for the treatment of certain hematologic cancers, where selectin-mediated cell
adhesion and migration is known to play a key role in the disease process.
About Sickle Cell Disease and Vaso-Occlusive Crisis
Vaso-occlusive crisis is the main clinical feature of sickle cell disease, often
resulting in significant clinical complications, and sometimes death. Currently,
there are no mechanism-based therapies for treatment of vaso-occlusive crisis.
Treatment consists primarily of supportive therapy in the form of hydration and
pain control, typically requiring hospitalization for five to six days. There
are over 75,000 hospitalizations per year associated with vaso-occlusive crisis
in the US.
About Children`s Hospital & Research Center Oakland
Children`s Hospital & Research Center Oakland is Northern California`s only
freestanding and independent children`s hospital. Children`s is a leader in many
pediatric specialties including neonatology, cardiology, neurosurgery and
intensive care. The hospital is a designated Level 1 pediatric trauma center and
has the largest pediatric critical care facility in the region. Children`s
Hospital has 190 licensed beds, 201 hospital-based physicians in 30 specialties,
more than 2,600 employees and an annual operating budget of $312 million.
Children`s research arm, Children`s Hospital Oakland Research Institute
(CHORI),is internationally renowned for taking state-of-the-art basic and
clinical research to the bedside with interventions for treating and preventing
human disease. CHORI has 300 staffers, a budget of about $50 million, and is
ranked among the nation`s top 10 research centers in National Institutes of
Health funding to children`s hospitals. CHORI is a leader in translational
research, developing new vaccines for infectious diseases, and discovering new
treatment protocols for previously fatal or debilitating conditions including
cancer, sickle cell anemia, thalassemia, diabetes, asthma, HIV/AIDS, pediatric
obesity, nutritional deficiencies, birth defects, hemophilia and cystic
fibrosis. For more information, go to www.childrenshospitaloakland.org.
About GlycoMimetics, Inc.
GlycoMimetics is a privately-held biotechnology company that capitalizes on
advances in the field of glycobiology. The company uses rational design of small
molecule drugs that mimic the functions of bioactive carbohydrates to develop
new drug candidates. The company's initial focus is on therapeutics to treat
inflammation, cancer, and infectious diseases. For additional information visit
the company's web site: http://www.glycomimetics.com.
GlycoMimetics, Inc. (GMI)
Andrew Barrett, 240-243-1220
Copyright Business Wire 2009
http://www.reuters.com/article/pressRelease/idUS174025+03-Sep-2009+BW20090903
Sorry, I certainly do not know the answer to your question.
Men should know their 'sickle status'
Published: Wednesday | September 9, 2009
One in every 10 Jamaicans carries the gene for sickle-cell disease. For every 150 live births, one baby is born with sickle-cell disease. This means about 260 babies with sickle-cell disease are born in Jamaica each year.
Clearly, every man should know about this genetic disease and how it affects him, his family and community. The Sickle Cell Unit of the University of the West Indies recently published clinical-care guidelines for this critical disease. Here are some important facts about sickle-cell disease from the guidelines.
What is sickle cell disease?
Sickle-cell disease is a condition of red blood cells where the red pigment (called haemoglobin) causes the cells to acquire a sickle shape rather than the normal doughnut shape. These sickle-shaped red blood cells are easily destroyed, causing the sufferers to have weak blood (anaemia). The sickle cells clog tiny blood vessels resulting in pain, strokes in childhood and other complications.
How do you test for sickle-cell disease?
There is a simple screening blood test which identifies both the sickle-cell trait and sickle-cell disease. A further test using electrophoresis will define the genotype of the person's haemoglobin. A person with sickle-cell disease may have only the sickle genotype (SS disease) or the sickle genotype with some other abnormality. Every man should do this test in order to determine his 'sickle status'.
Screening for sickle-cell disease
Screening for sickle-cell disease occurs at birth at the Victoria Jubilee Hospital, Spanish Town Hospital and the University Hospital of the West Indies. Unfortunately, this only accounts for about 35 per cent of newborns in Jamaica. Thus, about 170 babies born with sickle-cell disease are missed at birth, which results in late identification of the problem.
How do you get sickle-cell disease?
Sickle-cell disease is a genetic disease inherited from both parents. If a man has the sickle-cell trait, he has a 50 per cent chance of passing the sickle genotype to his children. If he has sickle-cell disease, he will most certainly pass this genotype to his children
When a baby is born with the SS haemoglobin genotype; one S haemoglobin genotype has come from each parent. When the baby has one S haemoglobin and a normal (A) haemoglobin genotype, then the baby will have the sickle-cell trait. A man should know his 'sickle status', as well as the 'sickle status' of his sexual partner, since this will determine the likelihood of having children with sickle-cell disease.
Dr Pauline Williams-Green is a family physician and president of the Caribbean College of Family Physicians; email: yourhealth@ gleanerjm.com.
http://www.jamaica-gleaner.com/gleaner/20090909/health/health5.html
UNITED STATES BANKRUPTCY COURT
- NORTHERN DISTRICT OF ILLINOIS -
THE HONORABLE JACK SCHMETTERER, PRESIDING
LOCATION: COURTROOM 682
EASTERN DIVISION
Friday, September 11, 2009
Updated 09/09/2009 @ 12:08:PM CST
11:00 AM
08bk30512
This[176]
Orig[137] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 6 Filed by Douglas S Draper on behalf of Xechem Inc.
08bk30512
This[176]
Orig[136] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 7 Filed by Douglas S Draper on behalf of Xechem Inc.
08bk30512
This[176]
Orig[138] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 9,10 Filed by Douglas S Draper on behalf of Xechem Inc.
08bk30513
This[124]
Orig[74] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 25 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[124]
Orig[71] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 30 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[124]
Orig[70] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 32 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[124]
Orig[64] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 33 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[124]
Orig[66] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 41 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[124]
Orig[72] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 41 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[124]
Orig[69] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 42 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[124]
Orig[65] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 45 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[124]
Orig[67] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 57 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[127]
Orig[119] XECHEM INTERNATIONAL, INC. CH. 11
Incorrect pdf, filer notified Notice of Motion and Motion to Allow Claim(s) # 57. Filed by William J Factor on behalf of Ramesh Pandey.
08bk30513
This[124]
Orig[75] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) of Omnibus Objection to Overstated Proofs of Claim Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[128]
Orig[75] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) of Omnibus Objection to Overstated Proofs of Claim Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[124]
Orig[76] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) of Omnibus Objection to Late-Filed Proofs of Claim Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[128]
Orig[76] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) of Omnibus Objection to Late-Filed Proofs of Claim Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[125]
Orig[82] XECHEM INTERNATIONAL, INC. CH. 11
Incorrect PDF-Filer Notified to Refile Notice of Motion and Motion to Disallow Omnibus Objection to Overstated Proofs of Claim Filed by Stephen A Metz on behalf of Renuka Misra Ph D.
08bk30513
This[126]
Orig[87] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Motion and Motion to Disallow Omnibus Objection to Overstated Proofs of Claim Filed by Stephen A Metz on behalf of Renuka Misra Ph D.
08bk30512
This[175] XECHEM INC CH. 11
Status Hearing Hearing Continued . Status hearing
09ap00581
This[5] XECHEM INC 08BK30512, XECHEM INTERNATIONAL, INC. V. MISRA PH D AP
Status Hearing Hearing Continued . Status hearing
08bk30513
This[130]
Orig[66] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 41 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[131]
Orig[67] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 57 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[132]
Orig[64] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 33 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[133]
Orig[65] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 45 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
pls check lamontef@collegefundsoftware.com /cheers ~ Steve
New Clues to How Cells Stay in Shape as Salinity Shifts
FOR FURTHER
INFORMATION:
Jennifer Michalowski
(301) 215-8576
michalow@hhmi.org
Howard Hughes
Medical Institute
4000 Jones Bridge Road Chevy Chase, MD 20815-6789
(301) 215-8500
August 07, 2009
Image shows ion cotransporter (blue) in the red blood cell membrane. When it is phosphorlated (white flash) it is inactive, but when it is dephosphorylated it is active, allowing potassium and chloride to leave the cell.
By deploying new proteomics technology, researchers have identified two molecular keys that unlock a crucial cellular door. This door releases salts from cells, helping cells maintain their size and shape and keeping them alive in the ever-changing salinity of their environment.
The finding, published in the August 7, 2009, issue of the journal Cell, could lead to new treatments for sickle cell disease, says Howard Hughes Medical Institute investigator Richard P. Lifton, who led the work.
“Cells have to be able to respond immediately to changes in salinity and solute in their environment.”
Richard P. Lifton
Maintaining proper cell size is a basic, vital cellular function. For instance, if a person drinks a few liters of water, the salinity of his or her blood drops. If unopposed, this would push water into cells and swell them to bursting. Conversely, eating a bag of salty potato chips would pull water out of cells, shriveling them to death. “Cells have to be able to respond immediately to changes in salinity and solute in their environment,” says Lifton, also at the Yale University School of Medicine. “It’s critical for virtually every cell in the body.”
To accomplish this, cells either release or take up chloride ions via cellular doors called cotransporters that move chloride – either into cells, together with sodium, or out of cells, along with potassium. These doors are embedded in the cell membrane. Potassium-chloride cotransporters open when the cell needs to reduce its chloride concentration, which in turn prevents water from entering and causing cell swelling. But exactly what opens these co-transporters has been unknown.
Lifton got onto the case in 2001, when he and his team discovered a new metabolic pathway that governs blood pressure. The key players in this pathway, Lifton found, were enzymes—specifically, protein kinases called WNKs (pronounced “winks”). “At the time we discovered them, their function was completely unknown,” says Lifton. “We knew that when the WNKs were mutated they caused high blood pressure in humans, but we knew nothing else about them.”
As his group investigated these proteins, it soon found that the WNKs helped regulate the flux of chloride ions into and out of cells. To learn more about how the WNKs were involved, Lifton focused on finding a link between WNKs and the potassium-chloride cotransporters, whose function as chloride chutes was well known. Because WNKs were protein kinases, which modify other proteins by attaching a phosphate group to them, Lifton reasoned that he should look for these modifications in the cotransporters. This atomic tag alters the function of the target protein in various ways, and over the past decade biologists have intensely studied phosphorylation and its role in myriad diseases.
Lifton wanted to see if the potassium-chloride co-transporters bore these marks. To do so, the team, led by lab member Jesse Rinehart, deployed a set of new technologies that can identify which segments of a protein carry a phosphate tag and precisely measure the fraction of proteins that carry this tag in different physiologic conditions. This technology, called quantitative phosphoproteomics, takes a cell, breaks all its proteins apart, then measures the mass of each protein fragment. A computer then sorts out which proteins these fragments are derived from and whether they carry a phosphate tag. “By the predictable change in mass that occurs due to phosphorylation, you can say, ‘Aha, I know that this particular site in this particular protein was phosphorylated,’” says Lifton.
The technique pinpointed two specific positions in the cotransporter where exposure to a low-salt environment rapidly altered the abundance of a phosphate tag. The team then made cells with mutant co-transporters that could not be phosphorylated at these sites and found that they had their doors swung wide open all the time, constantly releasing chloride. “You can watch these cells under a microscope shrivel up and turn into raisins,” Rinehart says.
Additional experiments with human red blood cells and mouse brain showed that phosphorylation of these sites correlated with the transporter’s activity in living cells. For example, in red blood cells that need to rid themselves of chloride, the number of cotransporters missing the phosphate tag rapidly increases. “Because the magnitude of these changes is relatively small, they would be very difficult to detect using conventional methods, but with the new quantitative techniques it was very clear,” says Lifton.
Further, when the researchers inhibited the activity of the WNK1 gene, this reduced the phosphorylation of the cotransporters’ regulatory sites. That means the WNKs are crucial to opening and closing the doors. More worked is needed to determine the precise pathway that connects them, Lifton says.
This deeper understanding of how the cotransporters operate may pay dividends for people with sickle cell disease, a common and devastating hereditary blood disorder. A severe attack, known as a sickle cell crisis, triggers pain as sickle-shaped red blood cells block blood vessels and reduce circulation. The red blood cells are believed to kink into their characteristic sickle shape after their cotransporters become active and reduce cell volume.
“A goal in sickle cell research has been to try to figure out how to maintain the hydration of red blood cells so they don’t become sickle cells,” says Pat Gallagher, Professor of Pediatrics at Yale and a co-author of the new study. The new work points to two possible drug development strategies. “One way is to understand what is triggering the dephosphorylation of these sites on the cotransporter and then prevent that. Or, you could augment the phosphorylation of these sites, which would keep the cotransporters closed,” Lifton says.
Illustration: Xvivo
http://www.hhmi.org/news/lifton20090807.html
I did change my siggy, however it won't show online (even while set as default) ... perhaps in time...
Are you 'back' ? ~ S
[edit] ok... i see finally the clearance certificate has been given on my siggy lol
Ahh, your optimism is a like a shining star...
The great thing is though, the future is very bright.
Thanks for your email re my contribution (paypal)
FIAT, thanks for posting this as it needs to be seen by everyone who has interest in Xechem. Much has gone on with this company that, while perhaps not different from what transpires in other 'low' profile corporations, has been done here in a rather transparent and sloppy way (in hindsight) imo.
It would seem that any remedial action by the court at this stage should be of benefit to all who have suffered losses with the performance of those in charge of Xechem, not just us who have lost financially but especially those who have lost in health and enjoyment of life as a result of the witholding and ultimate withdrawal of Nicosan from the market.
UNITED STATES BANKRUPTCY COURT
- NORTHERN DISTRICT OF ILLINOIS -
THE HONORABLE JACK SCHMETTERER, PRESIDING
LOCATION: COURTROOM 682
EASTERN DIVISION
Thursday, July 30, 2009
Updated 07/30/2009 @ 07:53:PM CST
09ap00358
This[1] XECHEM INC 08BK30512, XECHEM INTERNATIONAL, INC. V. NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND AP
Adversary case 09-00358. (14 (Recovery of money/property - other)), (91 (Declaratory judgment)): Complaint by XECHEM International, Inc. against National Institute for Pharmaceutical Research and Development, Babatunde Osotimehim, Uford S. Inyang.Fee Amount $250. Status hearing
09ap00358
This[12]
Orig[10] XECHEM INC 08BK30512, XECHEM INTERNATIONAL, INC. V. NATIONAL INSTITUTE FOR PHARMACEUTICAL RESEARCH AND AP
Notice of Motion and Motion to Dismiss Adversary Proceeding Filed by B Lane Hasler on behalf of Uford S. Inyang, National Institute for Pharmaceutical Research and Development, Babatunde Osotimehim.
http://www.ilnb.uscourts.gov/cci/0730A339.htm
Sickle cell group loses its state funding
The association has been a lifeline for those with the debilitating blood disorder.
DIRECTOR
Cheryl Freeman: She has led the organization since 1996, but will lose her job Friday.
By KIM ARCHER World Staff Writer
Published: 7/30/2009 2:27 AM
Last Modified: 7/30/2009 3:01 AM
Oklahomans with sickle cell disease have lost a source for financial help and treatment advice now that the Sickle Cell Disease Association of Oklahoma has lost its state funding.
The organization lost its $182,622 per year contract with the Oklahoma Department of Health on June 30. It accounted for 82 percent of group's budget.
State legislators eliminated the line item funding as part of recent budget cuts, said Cheryl R. Freeman, who has been executive director since 1996, but will lose her job Friday.
"I am just very disappointed," Freeman said. "I am blessed in that I'm a nurse. I can always find a job. But so many people just don't understand the special needs of sickle cell."
Freeman said three part-time employees were let go June 30. Her administrative assistant is expected to stay on as the board of directors tries to keep the organization afloat.
"I am very upset about this," said Tulsan Evelyn Fennell, whose 17-year-old granddaughter, Shambrille, has sickle cell disease.
"Now we don't have any options," she said. "I feel the Health Department turned its back on us. They didn't even bother to contact the families. I feel they really don't care."
The association helped educate Shambrille's teachers at Booker T. Washington about the disease. She has had strokes, countless blood transfusions, pain crises so bad she needed morphine and multiple hospitalizations.
"They helped us with utilities, with food when we needed it," Fennell said. "I can't tell you what it means to see an organization go down that has been there from the beginning. I feel it is a personal thing."
She said she and Shambrille likely will move to Atlanta where there are more resources after her granddaughter graduates from high school.
"I'm 68 years old and this state never progresses. It's one step ahead and three steps back," Fennell said. "I'm going to where they can give these kids a jump."
Sickle cell disease is an inherited blood disorder in which red blood cells have an abnormal type of hemoglobin. The red cells, which carry oxygen throughout the body, often become crescent-shaped and have difficulty moving through small blood vessels. People with the disease have frequent pain crises and are susceptible to strokes and organ damage.
Freeman said there are an estimated 1,100 Oklahomans with sickle cell disease and another 39,000 with hemoglobin trait conditions who will not get coordinated care through the organization. Services include education about the disease, finding treatment and services, financial support when children are hospitalized, hemoglobin trait screenings and more.
"As the economy started to tank after 9/11, we lost our support system," Freeman said. Some of its longtime corporate sponsors, such as Pepsi, Boeing and Williams Cos. pulled their support. That left the state contract as the organization's primary source of funding.
The group's working relationship with the Health Department was excellent, and had been since they started contracting in 1993. They provided the group names of newborns identified as having a hemoglobin trait or sickle cell disease so the group could encourage early intervention, Freeman said.
"We can get them into prophylactic antibiotics right away," she said. Before the screenings, many babies with sickle cell disease would die from sepsis, she said.
The screening, which began in 1991, identifies 15 to 18 newborn babies each year with the disease and 600 with the trait, Freeman said.
Derrick Boyd, 39, has sickle cell disease and is a board member of the Supporters of Families with Sickle Cell Disease support group.
The association's work with parents of newborns is crucial, he said, as is educating and screening teens with the sickle cell trait so that they can make informed choices when choosing their future spouse, he said.
"Overall, they were the voice and the face of the sickle cell community, both locally and nationally," he said.
The Tulsa group was one of about 59 member groups of the national Sickle Cell Disease Association of America.
http://www.tulsaworld.com/news/article.aspx?subjectid=17&articleid=20090730_17_A1_Shambr761528
Absolutely we would tend to agree, and I am also thinking the time might be right in Nigeria on this.
-------------- -------------- --------------
NIH stops trial of drug for sickle cell patients
10:46 AM, July 28, 2009
The National Institutes of Health has halted a clinical trial using sildenafil to treat pulmonary hypertension in sickle cell patients after preliminary results showed that the drug was actually increasing sickle crises rather than reducing them.
Sildenafil, sold by Pfizer as Cialis for erectile dysfunction and as Revatio for treating pulmonary hypertension in otherwise healthy adults, relaxes blood vessels, helping to prevent blockages that induce painful sickle crises, which can resemble heart attacks. The new study, sponsored by the NIH's National Heart, Lung and Blood Institute, was designed to show that it would work in adults with sickle cell disease as well. About 30% of sickle cell patients suffer from pulmonary hypertension, a debilitating condition of high blood pressure in the arteries thatcarry blood to the lungs. It can lead to heart failure and death. Researchers tested the patients' ability to walk rapidly on a treadmill for six minutes -- hence the name Walk-PHaSST for the trial.
With nearly a year left to go on the trial, officials halted it when a preliminary study of 33 patients who had completed at least 16 weeks of treatment showed that they were significantly more likely to develop painful sickle crises during the test. About 38% of those receiving the drug had sickle crises, compared with 8% of those receiving a placebo. No deaths were observed.
Because the complications observed in the trial were specific to sickle cell patients, researchers said there is no risk to others using the drug for pulmonary hypertension. The agency recommended that physicians treating sickle cell patients off-label with the drug taper it off over a period of three to seven days to avoid problems associated with abrupt withdrawal.
-- Thomas H. Maugh II
http://latimesblogs.latimes.com/booster_shots/2009/07/nih-stops-trial-for-lung-disease-in-sickle-cell-patients.html
Girl raises money to find sickle cell cure
By Heather Carney
hcarney@patuxent.com
Posted 7/30/09
Seven-year-old Nia Smith, right, chats with her friend, Aislynn Riggs, 8, July 25 while operating a lemonade stand in Owen Brown intended to raise money for sickle cell research. Nia, who has sickle cell anemia, hopes to raise $10,000 for her cause with help from family and friends. (Staff photo by Drew Anthony Smith)
Saturday, July 25 was one of Nia Smith's good days.
The 7-year-old Columbia girl, who has sickle cell anemia, wasn't suffering from pain in her back or legs or running a dangerously high fever. Instead she was brimming with energy, running and giggling, playing and working on a warm summer day with other children in her neighborhood.
Nia was selling lemonade and cookies to raise money for "Nia Smith's Lemonade Stand," to support sickle cell research.
It was part of a fundraising drive that Nia and her family hope will raise $10,000 for sickle cell research and for families with chronically ill children. The funds will be managed by Johns Hopkins Hospital, where Nia receives her care.
"We didn't want this money to support only sickle cell research, we wanted this to be for families, too," Avis Miner, Nia's grandmother, said.
Miner helped organize the lemonade stand, but said it was Nia's idea.
"We only planned this five days ago when Nia was asking me why her disease didn't have a cure," Miner said. "I explained to her that you needed money to research for a cure and that's how we decided to do this."
Nia was diagnosed with sickle cell anemia when she was 12 months old. Sickle cell is an inherited blood disease that affects the red blood cells, causing them to become sickle-shaped and making it difficult for them to move through small blood vessels. The cells clump together and block blood vessels that lead to the limbs and organs, causing pain, serious infections and organ damage.
People who have sickle cell anemia are born with it. They inherit two copies of the sickle cell gene -- one from each parent. The disease does not have a cure.
On the day of the lemonade sale, Nia, dressed for the occasion in a lemon-slice printed blouse, was surrounded by her grandmother and grandfather, two aunts and various other family members, not to mention a handful of neighborhood friends all between the ages of 2 and 9.
Signs posted along Winter Rose Path, in Columbia, read: "Support Sickle Cell Research, 50 cents for lemonade, cookie free with donation."
"We squeezed lemonade all night long. ... It's really homemade," said Nia, who will be a second-grader at Cradlerock School in the fall.
In between customers, the children sat in a circle, anxiously waiting for their turn to be "goose" in a spirited game of "duck-duck-goose." But when a customer approached the table, they jumped up from their seats to collect the donation in a shoe box and serve up the homemade lemonade.
One neighborhood customer even returned to the stand with a second donation.
"I wanted the young ladies to be successful," explained Pete Chadwick, who lives nearby. He contributed an additional $10.
Among the other customers were the local mailman, Nia's clinicians and other families affected by the sickle cell disease.
Nia raised more than $260 during the three-hour lemonade sale, Miner said, and the family will continue to collect donations until they reach their goal of $10,000.
The ambitious young Nia already has another fundraising event lined up.
"Nia told me that she wants to hold a kids art auction," Miner said. "The theme is going to be 'It's a Wonderful Life.'"
To donate, reference Nia Smith Fund and make checks payable to:
Johns Hopkins Children's Center
100 N. Charles St., Suite 200
Baltimore, MD 21201
http://www.theviewnewspapers.com/news/64173/girl-raises-money-find-sickle-cell-cure/
Putting the "Cell" in Cell Phone: Adapter Turns Its Camera into a Microscope
A low-cost adapter for cell phone cameras can capture images of abnormal cells and parasites
By Mandy Kendrick
July 21, 2009 | 0 comments
CellScope prototype
David Breslauer/UC Berkeley
A few years ago University of California, Berkeley, professor Daniel Fletcher challenged the undergraduate students in his optics and microscopy course to develop an instrument using only a cell phone and a few objective lenses. It was not until after the project began that Fletcher and the students realized they had created a powerful yet inexpensive instrument that could potentially be used to test for diseases common in developing countries, such as malaria, sickle-cell anemia and tuberculosis.
These diseases in particular have wreaked havoc in Africa. In 2003 in the 10 African countries with available data, 11,875,108 people had malaria, according to the World Health Organization (WHO). Approximately 300,000 infants are born in Africa each year with sickle- cell anemia, and tuberculosis is the leading killer of people with HIV and in 2007 alone infected an estimated 1.9 million people in sub-Saharan Africa.
Financial limitations prevent the diagnosis and treatment of these diseases. According to Dina Sigano, a research scientist who has volunteered at missionary hospitals in Kpele Tsiko, Togo, in west Africa and Andhra Pradesh in India, "Getting functioning equipment like the light microscopes needed to identify malaria is a challenge. " Laboratory-grade versions cost thousands of dollars, and Sigano notes that once equipment is purchased there is no money to maintain and repair it.
Fletcher and his colleagues believe that their device, which they call the CellScope, will provide an inexpensive alternative to the microscopes. The group made a removable adapter that fits over the camera lens on a standard Nokia N73 cell phone. David Breslauer, lead author on the study published in PLoS One, demonstrates the adapter in a video on the university's Web site. It comprises inexpensive standard microscope eyepieces and objective lenses, along with high-power LEDs, which illuminate the object.
To determine the usefulness of the CellScope, the group obtained and analyzed samples from patients confirmed to have malaria and sickle-cell anemia. Petri dishes containing each sample were clipped onto the end of the adaptor and magnified by the lenses. The phone's camera captured the enlarged images of the cells. The malaria-infected blood cells had turned blue with the addition of Giemsa stain and could clearly be seen on the cell phone screen; the irregular crescent moon–shaped sickle cells were easy to spot, as well.
Testing for tuberculosis was trickier. Currently, the best method is to stain cells with a dye that will fluoresce when the pathogen is present and use a fluorescent microscope—a variation of the light microscope— to see the glow. Such microscopes, however, cost tens of thousands of dollars.
While developing the CellScope, Brelauer's group noticed that blue light-emitting diodes provide enough light to trigger this fluorescence. The discovery, he says, "was somewhat serendipitous. It so happened that we were working on this at the same time that LED technology started becoming affordable." The researchers added blue LEDs to the adapter, at a cost of about $10 each, and each diode lasts about 50,000 hours, according to Breslauer. The group even had room to add filters, which are used in fluorescent microscopes to block extraneous light from contaminating the image.
http://www.scientificamerican.com/article.cfm?id=cell-phone-adapter-becomes-microscope
That's an interesting read fox, mostly over my head (of course) but nice to see such detail and exactness as it applies to the productin of Niprisan. I can see how easy it would be for Dr. Swift to mess up the potency and efficacy without much meddling, even if his intent was to 'improve' the production methodology. ... not that I am giving him the benefit of the doubt here.
I can only echo Larrywh's comments in post # 197026.
What might you have heard re the product Raven's last post?
UNITED STATES BANKRUPTCY COURT
- NORTHERN DISTRICT OF ILLINOIS -
THE HONORABLE JACK SCHMETTERER, PRESIDING
LOCATION: COURTROOM 682
EASTERN DIVISION
Friday, July 17, 2009
Updated 07/12/2009 @ 01:38:PM CST
11:00 AM
08bk30512
This[153]
Orig[138] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 9,10 Filed by Douglas S Draper on behalf of Xechem Inc.
08bk30512
This[153]
Orig[136] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 7 Filed by Douglas S Draper on behalf of Xechem Inc.
08bk30512
This[153]
Orig[137] XECHEM INC CH. 11
Notice of Hearing and Objection to Claim(s) 6 Filed by Douglas S Draper on behalf of Xechem Inc.
08bk30512
This[154]
Orig[136] XECHEM INC CH. 11
Notice of Hearing and Amended Objection to Claim(s) 7 Filed by Douglas S Draper on behalf of Xechem Inc (RE: [136] Objection to Claim).
08bk30512
This[155]
Orig[138] XECHEM INC CH. 11
Notice of Hearing and Amended Objection to Claim(s) 9,10 Filed by Douglas S Draper on behalf of Xechem Inc (RE: [138] Objection to Claim).
08bk30512
This[156]
Orig[137] XECHEM INC CH. 11
Notice of Hearing and Amended Objection to Claim(s) 6 Filed by Douglas S Draper on behalf of Xechem Inc (RE: [137] Objection to Claim).
08bk30512
This[144] XECHEM INC CH. 11
Status Hearing Chapter 11 Voluntary Petition Fee Amount $1039, Filed by Deborah W Fallis on behalf of XECHEM, Inc. (Fallis, Deborah)
08bk30513
This[95]
Orig[82] XECHEM INTERNATIONAL, INC. CH. 11
Incorrect PDF-Filer Notified to Refile Notice of Motion and Motion to Disallow Omnibus Objection to Overstated Proofs of Claim Filed by Stephen A Metz on behalf of Renuka Misra Ph D.
08bk30513
This[96]
Orig[87] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Motion and Motion to Disallow Omnibus Objection to Overstated Proofs of Claim Filed by Stephen A Metz on behalf of Renuka Misra Ph D.
08bk30513
This[100]
Orig[70] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 32 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [70] Objection to Claim).
08bk30513
This[101]
Orig[74] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 25 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [74] Objection to Claim).
08bk30513
This[102]
Orig[67] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 57 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [67] Objection to Claim).
08bk30513
This[103]
Orig[71] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 30 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [71] Objection to Claim).
08bk30513
This[104]
Orig[73] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 37 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [73] Objection to Claim).
08bk30513
This[105]
Orig[76] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 57,58,59,60,61 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [76] Objection to Claim).
08bk30513
This[106]
Orig[72] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 41 Filed by Douglas S Draper on behalf of XECHEM International, Inc. (RE: [72] Objection to Claim).
08bk30513
This[107]
Orig[75] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Amended Objection to Claim(s) 25,32,37,38,41,50,58,60 Filed by Deborah W Fallis on behalf of XECHEM International, Inc. (RE: [75] Objection to Claim).
08bk30513
This[97]
Orig[69] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 42 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[97]
Orig[67] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 57 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[97]
Orig[74] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 25 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[97]
Orig[70] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 32 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[97]
Orig[66] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 41 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[97]
Orig[65] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 45 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[97]
Orig[64] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 33 Filed by Robert E Richards on behalf of The Official Committee of Unsecured Creditors.
08bk30513
This[97]
Orig[72] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 41 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[97]
Orig[76] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) of Omnibus Objection to Late-Filed Proofs of Claim Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[97]
Orig[68] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 57 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[97]
Orig[71] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) 30 Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[97]
Orig[75] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Hearing and Objection to Claim(s) of Omnibus Objection to Overstated Proofs of Claim Filed by Douglas S Draper on behalf of XECHEM International, Inc..
08bk30513
This[119] XECHEM INTERNATIONAL, INC. CH. 11
Notice of Motion and Motion to Allow Claim(s) # 57. Filed by William J Factor on behalf of Ramesh Pandey.
08bk30512
This[167] XECHEM INC CH. 11
Notice of Motion and Motion for Leave to to File Adersary Complaint Filed by Elliot Wiczer on behalf of Shekhar Basu.
--------------------------------
Tuesday, July 21, 2009
Updated 07/12/2009 @ 01:38:PM CST
11:00 AM
08bk30512
This[164] XECHEM INC CH. 11
Order Scheduling . Civil Contempt Hearing against LeMonte Forthun scheduled for 7/21/2009 at 11:00 AM at 219 South Dearborn, Courtroom 682, Chicago, Illinois 60604. Signed on 7/7/2009 (Williams, Daphne)
08bk30512
This[163]
Orig[146] XECHEM INC CH. 11
Notice of Motion and Motion to Compel Production Pursuant to March 20 Rule 2004 Order Filed by Robert E Richards on behalf of Official Committee of Unsecured Creditors of Xechem, Inc. et al..
Thanks for posting this! Your resiliance is Wonderful! eom
Certainly you could count on several of us visiting you at your cell if you should so choose to stick to principles lol... however we do prefer the direction you are leaning.
Anybody else have to produce emails? Guess you should print them on 'recycled' paper since the emails are being 'reused'?
I think it means that Xechem is failing in it's requiremnet to disclose pertinent info, but cannot say this for certain. Monty or Elis can probably shed more light on this.
UNITED STATES BANKRUPTCY COURT
- NORTHERN DISTRICT OF ILLINOIS -
THE HONORABLE JACK SCHMETTERER, PRESIDING
LOCATION: COURTROOM 682
EASTERN DIVISION
Tuesday, July 07, 2009
Updated 06/26/2009 @ 08:38:AM CST
08bk30512
This[160]
Orig[146] XECHEM INC CH. 11
Notice of Motion and Motion to Compel Production Pursuant to March 20 Rule 2004 Order Filed by Robert E Richards on behalf of Official Committee of Unsecured Creditors of Xechem, Inc. et al..
Sometimes the group just get's a little ticked when folk do not peruse the ibox prior to posting q's imo... in any event, yes indeed we are looooooong term investors who are just a little ticked off at the performance and morals of the current BOD.
UN chief lends voice to raise awareness of sickle-cell anaemia
www.chinaview.cn 2009-06-20 00:54:13
UNITED NATIONS, June 19 (Xinhua) -- UN Secretary-General Ban Ki-moon Friday urged governments, civil society and all other partners to do their part to improve the quality of life of people with sickle-cell anaemia and enable them to live full, productive lives.
In a message on the occasion of the first World Sickle-Cell Anaemia Awareness Day, Ban recalled the "welcome step" taken by the General Assembly last December of adopting a resolution recognizing the disease as a public health problem.
He said that sickle-cell anaemia is an inherited condition that affects hundreds of thousands of babies born each year, mostly in low- and middle-income countries.
"I am pleased to lend my voice to the effort to raise global awareness about it. The more people understand the disease, the better we can respond," he said, adding that understanding is also critical to eliminating the harmful prejudices associated with the condition.
Ban said that although sickle-cell anaemia cannot be cured, it can be managed through simple measures such as increasing fluid intake, pursuing a healthy diet, taking folic acid supplements and taking medication as needed.
"We must ensure that these affordable, common-sense interventions are available to all people suffering from the disease so that they can enjoy healthy and productive lives," he said.
For its part, the UN, in working to strengthen health systems worldwide, encourages research on the disease and helps build capacity to conduct screenings for it, he added.
On December 18, 2008, the General Assembly adopted a resolution calling for the recognition of sickle-cell anaemia as a public health problem and "one of the world's foremost genetic diseases." It also called for member states and the UN system to raise awareness of sickle-cell anaemia on June 19 every year at the national and international level.
http://news.xinhuanet.com/english/2009-06/20/content_11570401.htm
Yes, from many years ago now, he was a bit of a pioneer - if you will... quite a few have emulated his rather original 'think and grow rich' imo... good stuff in many ways.
UNITED STATES BANKRUPTCY COURT
- NORTHERN DISTRICT OF ILLINOIS -
THE HONORABLE JACK SCHMETTERER, PRESIDING
LOCATION: COURTROOM 682
EASTERN DIVISION
Tuesday, June 30, 2009
Updated 06/23/2009 @ 09:38:AM CST
08bk30512
This[161] XECHEM INC CH. 11
Notice of Motion and Routine Routine Motion To Substitute Attorney Filed by William J Factor on behalf of Dr. Ramesh Pandey.
http://www.ilnb.uscourts.gov/cci/0630A339.htm
World Sickle Cell Disease Day today
Published on Thursday, June 18, 2009
The Cayman Islands joins the United Nations in observing the first annual Sickle Cell Disease World Day on Thursday, 19 June.
The worldwide event will raise awareness of the disease, and follows a United Nations General Assembly resolution adopted in December 2008 that recognizes sickle cell disease as a public health problem.
According to Public Health figures, there at present 33 persons in the Cayman Islands with sickle cell disease.
“We are fortunate to have facilities to diagnose sickle cell disease and to manage it. These patients do sometimes get painful crises because of damage to the bone marrow. It is a chronic disease, and management of sickle cell disease is treatment of symptoms and learning to live or cope with the help of health care professionals. Sickle cell testing is offered to all newborns in the Cayman Islands,” said Health Services Authority Genetics Coordinator Joy Merren.
“We also have a peer support group, the Sickle Cell Support Group, where family and patients come together to share experiences in coping with the disease, and educational sessions are organized for awareness and management of the disease. This group meets three to four times a year and is supported by the Public Health Department.
“If someone has sickle cell trait, it is important to know if one’s partner is also a carrier. If both parents are sickle cell carriers, then with each pregnancy, there is a 25 percent risk of having a child with sickle cell disease. Knowing ahead of time can help couples make informed reproductive choices. While sickle cell trait is mild, sickle cell disease is serious and can potentially affect every organ of the body.”
Patients with sickle cell disease can live lives optimally as they work together with family and health care workers in managing this disorder.
For further information, please contact Mrs Merren at (345) 244-2630.
What is Sickle Cell Disease?
Sickle cell disease is an inherited chronic disorder that affects red blood cells. It has a worldwide distribution, and is one of the most common genetic disorders.
All persons have two genes that make haemoglobin. Normal red blood cells contain haemoglobin A, a protein that helps red blood cells carry oxygen around the body. With sickle cell there is a different form of protein, haemoglobin S. With sickle cell disease, both genes are affected, causing severe symptoms.
Normal red blood cells are round, flat and very flexible. However, when the oxygen comes out of the red blood cells of sickle cell disease, the cell becomes stiff and takes on the shape of a sickle – hence, the name. The sickle cells clump together, are not able to squeeze through the small blood vessels, and so the sickle cells get destroyed more quickly. A normal red blood cell lives approximately 120 days but a sickle cell may only live 11 or 12 days.
What is Sickle Cell Trait?
When only one gene is affected, it is called sickle cell trait, or persons are called sickle cell carriers. Having sickle cell trait means that the person stays healthy under normal circumstances, and the main significance is that it can be passed on to one’s children. Persons with just the trait CANNOT later develop the disease.
How do I know if I have sickle cell trait?
A blood test can be done to determine if a person has the trait.
How is Sickle Cell Disorder inherited?
If a man and a woman are both sickle cell carriers, with each pregnancy, there is a:
• 25% chance of the child having the disease;
• 25% chance of the child being completely free from sickle cell; and
• 50% chance of the child having the sickle cell trait, i.e., being a carrier.
If only one parent is a carrier, then there is a:
• 50% chance of the child having the trait;
• 50% chance of the child being completely free of sickle; and
• NO chance of the child having the disease.
Symptoms:
• Anaemia, jaundice and gallstones due to rapid breakdown of the red blood cells
• Painful swelling of fingers and toes in babies
• Painful attacks of joints, back and abdomen as there may be damage to the bone marrow
• Infections may develop, such as pneumonia
• Leg ulcers may develop due to less oxygen to the lower legs
Managing the disease – some strategies:
• Full recommended immunizations plus pneumococcal vaccines
• Penicillin, starting from about 2 months of age to 5 years of age to help prevent serious infection
• Management of symptoms by using medications as needed
• Folic acid daily to help make new red cells
Please note: These are some of the management strategies. For further details, please consult your doctor.
(Source: Public Health Department)
Reads : 183
http://www.caymannetnews.com/news-16272--1-1---.html
Simply Amazing verbal discertation. Thanks for the alert. eom
Remember this fellow Xgemers?
House Resolution 99
By: Representatives Beasley-Teague of the 65th, Brooks of the 63rd, Lucas of the 139th, and Epps of the 128th
A RESOLUTION
Commending Xechem International, Inc.; and for other purposes.
WHEREAS, Xechem International, Inc. is a development stage biopharmaceutical company working on sickle cell disease, antimalarial, antiviral (including AIDS), anticancer, antifungal, and antibacterial products from natural sources, including microbial and marine organisms; and
WHEREAS, Xechem International´s mission includes bringing relief to people who suffer from "orphan" or rare diseases; and
WHEREAS, Xechem International´s recent focus and resources have been directed primarily toward the development and launch of NICOSANTM (or HEMOXINTM), a miracle drug for the management of sickle cell disease, which represents a monumental achievement for Xechem International and the people of Nigeria, where the drug was developed; and
WHEREAS, under the guiding hand of its chief executive officer, Dr. Ramesh Pandey, this extraordinary company has grown from its humble beginnings to become one of the leading biopharmeceutical businesses in the world; and
WHEREAS, it is abundantly fitting and proper that the impressive accomplishments of this amazing company be appropriately recognized.
NOW, THEREFORE, BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES that the members of this body commend Xechem International, Inc. for its many important contributions on behalf of persons in need and extend to it their best wishes for continued corporate growth, development, and success in the future.
BE IT FURTHER RESOLVED that the Clerk of the House of Representatives is authorized and directed to transmit an appropriate copy of this resolution to Dr. Ramesh Pandey.
http://wwwtom20graves.legis.state.ga.us/legis/2007_08/fulltext/hr99.htm
Sickle cell staff to be honoured
By MANDEEP SINGH, Posted on » Tuesday, June 09, 2009
A PRESSURE group, which claimed negligence was responsible for the deaths of seven sickle cell anaemia patients since the start of the year, is preparing to honour hospital staff. The Bahrain Society for Sickle Cell Anaemia Patient Care is organising a thank you ceremony for Salmaniya Medical Complex (SMC) staff charged with taking care of such patients.
Society chairman Zakareya Ebrahim Alkadhem, who has just emerged from a month at the hospital's intensive care unit (ICU) where he was treated for the condition, said it was important to recognise medical workers' efforts.
He said the staff should not be held responsible for the failings of Bahrain's medical system, which he claimed was at fault for alleged mistreatment of sickle cell anaemia sufferers.
He said 12 patients had died since the start of the year, but stressed five deaths could not be prevented.
"We feel at least seven could have been saved if timely medical attention had been given to them or beds available at the ICU."
Hospital authorities had admitted to the GDN their struggle to cope with a chronic bed shortage.
"The staff try their best. They are under severe pressure. We have no complaints against them," he said.
"If there is no medication available, there are not enough beds and staff are not managed properly, we have to blame the system - not individuals.
"We have to try to change the system and ask for more staff.
"We have been holding talks with authorities for a long time and things have been promised."
The society will organise the ceremony on June 19.
"We will honour doctors, nurses, hospital staff and members of the media," he said.
The ceremony, starting at 9am, will take place at the College of Health Sciences, Salmaniya.
Meanwhile, the society is waiting for final reports on investigations into the seven deaths.
Ibrahim Al Asfoor, 24, was the seventh to allegedly die due to a bed shortage on March 1.
Five who died in similar circumstances were Ali Mohammed, 55, on January 3; Zahra'a Umm Fadel Al Kabaz, 53, on January 9; Rabab Abdul Karim, 41, on January 20; Jaffer Mohammed Ahmed, from Karzakan, on February 1 and Najat Abdulla Ali, 44, on February 11.
A 10-year-old patient allegedly died because no beds were available, but his parents have asked for him to remain anonymous.
"Obviously, we would want to know what happened and whether investigations would lead to some corrective action," said Mr Alkadhem.
He said Health Minister Dr Faisal Al Hamer had assured the society that he would "go the extra mile" to ensure proper facilities for such patients.
"We expressed our concern that several patients had died allegedly due to a bed shortage and not being treated on time and the minister assured us he would ensure there would be no negligence and that all those found to be negligent would be severely dealt with."
mandeep@gdn.com.bh
http://www.gulf-daily-news.com/NewsDetails.aspx?storyid=252800